Market news

U.S. futures mixed as Vail Resorts fell after a Q4 loss miss despite beating sales estimates; several stocks also declined premarket.

Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study’s 72-week visit earlier this month. Chie

On Monday, Inventiva (NASDAQ:IVA) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and

Companies Reporting Before The Bell • Kandi Technologies Gr (NASDAQ:KNDI) is likely to report earnings for its first quarter. • Inventiva (NASDAQ:IVA) is expected to report quarterly loss at $0.20 per share on revenue

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026Cash runway guidance remains unchanged from July 30, 20262Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026Key highlights from the first half of 2026 and recent Company updatesManagement to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inventiva

Companies Reporting Before The Bell • Tamboran Resources (NYSE:TBN) is estimated to report quarterly loss at $0.30 per share on revenue of $3.82 million. Companies Reporting After The Bell • Inventiva (NASDAQ:IVA) is

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Tipranks Press Release.

Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and cardiac profile relative to TZDs and dual PPARα/γ agonists Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clin

Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference participation and timing of H1 2026 financial results update Daix (France), New York (New York, United States), September 2nd, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.

Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicin

Inventiva (IVA) said late Monday it appointed Chris Benecchi as chief operating officer. Benecchi

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the pres

Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the first half of 202

Detailed price information for Hca Holdings Inc (HCA-N) from The Globe and Mail including charting and trades.

Detailed price information for Alkermes Plc (ALKS-Q) from The Globe and Mail including charting and trades.

Inventiva SA ADR (IVA) has an average rating of buy and mean price target of $15.69, according to an

Inventiva S.A. (NASDAQ:IVA) is one of the best strong buy penny stocks to invest in now. Inventiva S.A. (NASDAQ:IVA) announced on July 9 the completion of the final step of the transactions previously announced on June 2, 2026, through the issuance of approximately 15.7 million new warrants to the European Investment Bank, along with the […]

Inventiva (ENXTPA:IVA) stock has been relatively flat in the latest session, leaving investors focused on how its clinical stage pipeline in MASH and rare diseases, together with recent share performance, shapes the current risk reward profile. See our latest analysis for Inventiva. Over the past year, Inventiva’s share price return has been mixed, with a 9.1% 1 month gain and a 15.4% decline over 3 months. The 1 year total shareholder return of 34.7% points to earlier buying interest that...

Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a...

Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.